A double-blind placebo controlled multicenter study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS).

Trial Profile

A double-blind placebo controlled multicenter study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs Dirucotide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MAESTRO-01
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Sep 2009 Data have been presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 27 Jul 2009 Primary endpoint time to disease progression as assessed using the Expanded Disability Status Scale (EDSS) has not been met, according to an Eli Lilly media release. On the basis of this result, the MAESTRO-02 trial has been discontinued.
    • 23 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top